Affibody has obtained a granted patent on the Microbead display technology, an in vitro selection system
STOCKHOLM, Sweden, 14 February 2007 – Affibody AB today announced that the European patent office has granted a patent application regarding a Microbead-based system to be used for rapid selection of Affibody® molecules and other small binding proteins. Last year the US patent office granted the Company a patent on this principle.
In contrast to selection principles based on biological systems, such as phage display, the Microbead display technology is a cell free system without the limiting factors associated with transformation of DNA into cells, enabling the creation of larger libraries. A further advantage is that all steps in the Microbead selection technology are performed in vitro, i.e. in the test tube, enabling automization of all unit operations. The US and EU patents are the first to be granted on this principle and derives from the first filed patents on a bead-based selection system.
Affibody AB is focusing on developing a pipeline of molecular imaging and targeted therapeutic products based on Affibody® molecules. The Company believes the Microbead display technology may be applicable also for selection of other binding molecules and intends to partner the technology to bring out its full potential.
Dr. Lars Abrahmsén, Chief Scientific Officer at Affibody AB, commented: “The Company has shown that this proprietary principle works in practice, while many other groups have tried in vain to get bead-based selection to work. This is an achievement based on work by two of Affibody’s founders, pioneers in this field.”
- Contact Information
- Lars Abrahmsén
- Chief Scientific Officer
- Affibody AB
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.